Laboratory for Human Molecular Genetics, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.
Faculty of Biology, University of Belgrade, 11158 Belgrade, Serbia.
Cells. 2022 Aug 15;11(16):2530. doi: 10.3390/cells11162530.
Glioblastoma (GBM) is the most common and highly lethal type of brain tumor, with poor survival despite advances in understanding its complexity. After current standard therapeutic treatment, including tumor resection, radiotherapy and concomitant chemotherapy with temozolomide, the median overall survival of patients with this type of tumor is less than 15 months. Thus, there is an urgent need for new insights into GBM molecular characteristics and progress in targeted therapy in order to improve clinical outcomes. The literature data revealed that a number of different signaling pathways are dysregulated in GBM. In this review, we intended to summarize and discuss current literature data and therapeutic modalities focused on targeting dysregulated signaling pathways in GBM. A better understanding of opportunities for targeting signaling pathways that influences malignant behavior of GBM cells might open the way for the development of novel GBM-targeted therapies.
胶质母细胞瘤（GBM）是最常见且致命的脑肿瘤类型，尽管对其复杂性的认识有所提高，但患者的生存率仍较差。在目前的标准治疗方法，包括肿瘤切除、放疗和替莫唑胺联合化疗后，这种类型肿瘤患者的中位总生存期不到 15 个月。因此，迫切需要深入了解 GBM 的分子特征和靶向治疗的进展，以改善临床结果。文献数据显示，GBM 中存在许多不同的信号通路失调。在这篇综述中，我们旨在总结和讨论目前针对 GBM 中失调信号通路的治疗方法和文献数据。更好地了解影响 GBM 细胞恶性行为的信号通路靶向治疗机会，可能为开发新的 GBM 靶向治疗方法开辟道路。
